Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$47.39 - $80.2 $56,536 - $95,678
-1,193 Closed
0 $0
Q1 2024

Aug 09, 2024

BUY
$17.4 - $94.5 $20,758 - $112,738
1,193 New
1,193 $97.8 Million
Q2 2023

Sep 08, 2023

BUY
$14.84 - $24.79 $7,420 - $12,395
500 New
500 $8.11 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Tucker Asset Management LLC Portfolio

Follow Tucker Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tucker Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tucker Asset Management LLC with notifications on news.